ARGX Key Statistics, Chart & Performance
The current stock price of ARGX is 901.17 USD. In the past month the price increased by 5.89%. In the past year, price increased by 44.62%.
ARGX Latest News, Press Relases and Analysis
ARGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ARGX
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1599
Phone: 31763030
ARGENX SE - ADR / ARGX FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the stock price of ARGENX SE - ADR today?
The current stock price of ARGX is 901.17 USD. The price decreased by -1.62% in the last trading session.
What is the dividend status of ARGENX SE - ADR?
ARGX does not pay a dividend.
How is the ChartMill rating for ARGENX SE - ADR?
ARGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ARGENX SE - ADR (ARGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARGX.
How many employees does ARGENX SE - ADR have?
ARGENX SE - ADR (ARGX) currently has 1599 employees.
Can you provide the market cap for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a market capitalization of 55.48B USD. This makes ARGX a Large Cap stock.
ARGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 89.75% of all stocks.
ARGX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ARGX. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability.
ARGX Financial Highlights
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 13.41. The EPS increased by 1512.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.97% | ||
| ROA | 17.84% | ||
| ROE | 21% | ||
| Debt/Equity | 0.01 |
ARGX Forecast & Estimates
25 analysts have analysed ARGX and the average price target is 978.22 USD. This implies a price increase of 8.55% is expected in the next year compared to the current price of 901.17.
For the next year, analysts expect an EPS growth of 939.88% and a revenue growth 94.97% for ARGX